tiprankstipranks
Ocugen Inc (OCGN)
NASDAQ:OCGN
US Market

Ocugen (OCGN) Earnings Dates, Call Summary & Reports

Compare
5,884 Followers

Earnings Data

Report Date
May 02, 2025
TBA Not Confirmed
Period Ending
2025 (Q1)
Consensus EPS Forecast
-0.06
Last Year’s EPS
-0.05
Same Quarter Last Year
Based on 3 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:Mar 05, 2025
|
% Change Since: 8.47%
|
Next Earnings Date:May 02, 2025
Earnings Call Sentiment|Positive
The earnings call for Ocugen highlighted several strategic advancements, including FDA alignment for an expedited clinical trial timeline, positive clinical trial results, and a strong financial position bolstered by recent funding. However, the company also reported increased net losses and higher expenses compared to the previous year. While the company faces financial challenges, the progress in clinical trials and regulatory advancements contribute positively to its outlook.
Company Guidance
During the call, Ocugen provided guidance on several key metrics and strategic initiatives for their gene therapy platform. They announced alignment with the FDA to advance a Phase 2/3 pivotal trial for OCU410ST, targeting Stargardt disease, potentially expediting their development timeline by two to three years. The company aims for three potential Biologics License Applications (BLAs) within the next three years: OCU400 in 2026, OCU410ST in 2027, and OCU410 in 2028. Ocugen secured $65 million in equity and debt financing in the latter half of 2024, extending their cash runway into the first quarter of 2026. They reported a net loss of $13.9 million for Q4 2024 and a full-year net loss of $54.1 million, with cash and restricted cash totaling $58.8 million as of December 31, 2024. The company continues to strategically advance their clinical programs, including OCU400 for retinitis pigmentosa, OCU410 for geographic atrophy, and OCU200 for diabetic macular edema.
FDA Alignment for Phase 2/3 Trial
Ocugen reached an alignment with the FDA to move forward with a Phase 2/3 pivotal confirmatory trial for OCU410ST BLA targeting Stargardt disease, potentially expediting their clinical development timeline by two to three years.
Secured Financing
Ocugen secured $65 million in equity and debt financings in the second half of 2024, extending their cash runway into the first quarter of 2026.
Positive Clinical Trial Results
OCU400 showed statistically significant improvement in visual function with a p-value of 0.005, and OCU410ST showed a significant p-value of 0.02 for visual acuity improvement in treated eyes.
Advanced Therapy Medicinal Product (ATMP) Classification
OCU400 and OCU410ST received ATMP classification from the European Medicines Agency, accelerating regulatory review timelines.
Strong Cash Position
Cash and restricted cash increased to $58.8 million as of December 31, 2024, compared to $39.5 million at the end of 2023.
---

Ocugen (OCGN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

OCGN Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
May 02, 20252025 (Q1)
-0.06 / -
-0.05
Mar 05, 20252024 (Q4)
-0.05 / -0.05
-0.03-66.67% (-0.02)
Nov 08, 20242024 (Q3)
-0.06 / -0.05
-0.0616.67% (<+0.01)
Aug 08, 20242024 (Q2)
-0.05 / -0.04
-0.160.00% (+0.06)
May 14, 20242024 (Q1)
- / -0.07
-0.077.14% (<+0.01)
Apr 02, 20242023 (Q4)
-0.06 / -0.05
-0.0728.57% (+0.02)
Nov 09, 20232023 (Q3)
-0.07 / -0.06
-0.140.00% (+0.04)
Aug 21, 20232023 (Q2)
-0.07 / -0.10
-0.09-11.11% (-0.01)
May 05, 20232023 (Q1)
-0.11 / -0.07
-0.0922.22% (+0.02)
Feb 28, 20232022 (Q4)
-0.10 / -0.10
-0.07-42.86% (-0.03)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

OCGN Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Mar 05, 2025$0.59$0.57-3.39%
Nov 08, 2024$1.08$0.99-8.33%
Aug 08, 2024$1.18$1.28+8.47%
May 14, 2024$1.81$1.70-6.08%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Ocugen Inc (OCGN) report earnings?
Ocugen Inc (OCGN) is schdueled to report earning on May 02, 2025, TBA Not Confirmed.
    What is Ocugen Inc (OCGN) earnings time?
    Ocugen Inc (OCGN) earnings time is at May 02, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is OCGN EPS forecast?
          OCGN EPS forecast for the fiscal quarter 2025 (Q1) is -0.06.
            ---

            Ocugen (OCGN) Earnings News

            OCGN Earnings: Ocugen Stock Jumps on Q4 Results & Development Updates
            Premium
            Market News
            OCGN Earnings: Ocugen Stock Jumps on Q4 Results & Development Updates
            21d ago
            OCGN Earnings: Ocugen’s Q3 Results Disappoint
            Premium
            Market News
            OCGN Earnings: Ocugen’s Q3 Results Disappoint
            5M ago
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis